Showing 1 - 6 results of 6 for search 'Iris Kersten', query time: 0.03s Refine Results
  1. 1
    Identification of cerebrospinal fluid biomarkers for parkinsonism using a proteomics approach

    Identification of cerebrospinal fluid biomarkers for parkinsonism using a proteomics approach by Tainá M. Marques, Anouke van Rumund, Iris Kersten, Ilona B. Bruinsma, Hans J.C.T. Wessels, Jolein Gloerich, Charlotte Kaffa, Rianne A. J. Esselink, Bastiaan R. Bloem, H. Bea Kuiperij, Marcel M. Verbeek

    Published 2021-11-01
    Get full text
    Article
  2. 2
    Cerebrospinal fluid shotgun proteomics identifies distinct proteomic patterns in cerebral amyloid angiopathy rodent models and human patients

    Cerebrospinal fluid shotgun proteomics identifies distinct proteomic patterns in cerebral amyloid angiopathy rodent models and human patients by Marc Vervuurt, Joseph M. Schrader, Anna M. de Kort, Iris Kersten, Hans J. C. T. Wessels, Catharina J. M. Klijn, Floris H. B. M. Schreuder, H. Bea Kuiperij, Jolein Gloerich, William E. Van Nostrand, Marcel M. Verbeek

    Published 2024-01-01
    Get full text
    Article
  3. 3
    Correction to: Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer’s disease, but not in cerebral amyloid angiopathy

    Correction to: Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer’s disease, but not in cerebral amyloid angiopathy by Anna M. De Kort, H. Bea Kuiperij, Daniel Alcolea, Iris Kersten, Alexandra A. M. Versleijen, Steven M. Greenberg, Erik Stoops, Floris H. B. M. Schreuder, Catharina J. M. Klijn, Alberto Lleó, Jurgen A. H. R. Claassen, Marcel M. Verbeek

    Published 2021-11-01
    Get full text
    Article
  4. 4
    Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer’s disease, but not in cerebral amyloid angiopathy

    Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer’s disease, but not in cerebral amyloid angiopathy by Anna M. De Kort, H. Bea Kuiperij, Daniel Alcolea, Iris Kersten, Alexandra A. M. Versleijen, Steven M. Greenberg, Erik Stoops, Floris H. B. M. Schreuder, Catharina J. M. Klijn, Alberto Lleó, Jurgen A. H. R. Claassen, Marcel M. Verbeek

    Published 2021-09-01
    Get full text
    Article
  5. 5
    Decreased ratios of matrix metalloproteinases to tissue-type inhibitors in cerebrospinal fluid in sporadic and hereditary cerebral amyloid angiopathy

    Decreased ratios of matrix metalloproteinases to tissue-type inhibitors in cerebrospinal fluid in sporadic and hereditary cerebral amyloid angiopathy by Marc Vervuurt, Anna M. de Kort, Lieke Jäkel, Iris Kersten, Wilson F. Abdo, Floris H. B. M. Schreuder, Ingeborg Rasing, Gisela M. Terwindt, Marieke J. H. Wermer, Steven M. Greenberg, Catharina J. M. Klijn, H. Bea Kuiperij, Marcel M. Verbeek

    Published 2023-01-01
    Get full text
    Article
  6. 6
    Plasma amyloid beta 42 is a biomarker for patients with hereditary, but not sporadic, cerebral amyloid angiopathy

    Plasma amyloid beta 42 is a biomarker for patients with hereditary, but not sporadic, cerebral amyloid angiopathy by Anna M. de Kort, H. Bea Kuiperij, Lieke Jäkel, Iris Kersten, Ingeborg Rasing, Ellis S. van Etten, Sanneke van Rooden, Matthias J. P. van Osch, Marieke J. H. Wermer, Gisela M. Terwindt, Floris H. B. M. Schreuder, Catharina J. M. Klijn, Marcel M. Verbeek

    Published 2023-06-01
    Get full text
    Article

Search Tools: